Newsletter | May 27, 2025

05.27.25 -- Oral Drug Delivery For Breast Cancer Prevention

FEATURED EDITORIAL

Combination Products: US And EU Requirements And Harmonization

In the U.S. and the EU, there are differences in the terminology used for combination products, as well as in the format and location of the information in the dossiers. This article also proposes a harmonized approach for CTD Module 3.

Oral Drug Delivery For Breast Cancer Prevention

In this episode of Sit and Deliver, host Tom von Gunden talks with Atossa Therapeutics CEO Steven Quay about oral drug delivery for early intervention in patients at high risk of breast cancer. The discussion covers formulations, coatings, and dosing for orally administered, cancer-preventative approaches to reducing breast density. 

INDUSTRY INSIGHTS

'Smart Devices' vs. 'Smart Design' In User-Centric Autoinjector Design

Oval Medical has developed a novel Prefilled Primary Drug Container that resolves many compatibility and functionality issues associated with traditional glass syringes and rubber plunger technologies.

Formulation Technologies For Dry Powder Inhalation

Examine challenges and key considerations for spray-dried formulations for inhalation, along with a review of current technologies and approved products utilizing particle engineering approaches.

Lifecycle Planning For Containment And Delivery Of Biologics Products

Read more about trends in the biologics market that could impact the lifecycle strategies for your drug product and steps you can take around drug packaging early in development.

Sterilization Methods And Stopper Performance In Delivery Systems

Three studies focus on a product designed to address unmet needs in subcutaneous drug therapies for chronic diseases, including sterilization methods and a Human Factors evaluation.

SOLUTIONS

Accelerating Gene Therapy With HITSCAN Platform

Formulation And Analytical Tour

AdvaTab Orally Disintegrating Tablet Technology